PORTOLA VALLEY, Calif., Oct. 12 /PRNewswire/ -- Spectros, developer and manufacturer of the T-Stat VLS Tissue Oximeter announces its success in the reconstructive plastic surgery market.
Spectros has begun to see great interest in their VLS white light technology in the reconstructive plastic surgery market. The T-Stat can be easily used to monitor free flaps post operatively. The concept is not new to the market, however T-Stat's patented VLS white light technology is. T-Stat's state-of-the-art second-generation technology yields reproducible and reliable results. Previously, this need was unmet in the clinical world. The need is not only for a noninvasive and easy to use device, but to display an absolute, simple-to-understand, and rapid-responding number that surgeons can trust and treat to. Spectros has put great effort into making this happen by collaborating with microsurgeons, vascular surgeons and clinicians.
"The response to the technology in this reconstructive plastic surgery market has really begun to take off. Familiarity with the T-Stat it is providing practicing surgeons with a confidence in monitoring free flaps that wasn't available before and that is being shared widely among the microsurgery community," stated Elizabeth van Thillo, Director of Marketing.
Spectros attended The American Society of Plastic Surgeons (ASPS) Plastic Surgery 2010 in Toronto at the Metro Toronto Convention Centre, October 1–5, 2010. "This is quickly becoming a forward moving market for Spectros and we plan on continuing to attend these microsurgery conferences to better understand the market and to present the papers currently being worked on throughout the U.S."
Spectros markets and licenses advanced molecular sensing and imaging devices that shed light on ischemia and cancer. The company's champion product, the T-Stat VLS Tissue Oximeter, is the first medical device FDA-approved as sensitive to ischemia, an insufficient supply of oxygen to tissue. T-Stat is the only commercially-available tissue oximeter that utilizes state-of-the-art multispectral visible light spectroscopy (VLS) technology. The non-invasive T-Stat VLS system is used clinically to provide a continuous and real-time absolute value, utilizing 260 wavelengths, over the competing NIRS oximeter product lines that only use 2-4.
Spectros also develops molecular diagnostic tools for breast and prostate cancer, currently in phase I/II clinical trials supported by the National Cancer Institute. Spectros is a venture-supported private concern and markets its products in the U.S. and internationally.
(Note: Forward-looking statements are intended as a guide only, and do not constitute an offer for investment nor a guarantee of future events or returns. Certain Spectros applications described above have not been reviewed and approved by the FDA, and are therefore labeled for investigational use only. T-Stat and Continuum are trademarks of the Spectros Corporation.).